MeaslesNCT01602094
Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
An observational study of Measles, run by Queen Saovabha Memorial Institute at 1 site in Thailand.
Trial summary
Prevalence of participants who have protective immunity to measles virus is less than ninety percent. Predictor of adequate measles antibody levels include the following : History of measles infection History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)… Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Measles
- How many people
- 550 participants
- Where
- 1 siteThailand
- Study dates
- Jul 2012to Mar 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Health Thai participant age 18-30 years old.
Who may be able to join
- Age 18-30 years old
Who cannot join
- Last measles vaccination less than 10 years of age
- Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
- Receiving blood or blood product within 3 months
- Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response
Trial locations and contacts
1 site in 1 country.
Thailand1 site
Queen Saovabha Memorial Institute
Bangkok, Bangkok, 10330
Maneerat Benjavongkulchai, R.N., 662-252-0161-4 ext. 124, neowmanee@yahoo.com
Jaruboot Angsanakul, M.D.
About this study
Prevalence of participants who have protective immunity to measles virus is less than ninety percent.
Predictor of adequate measles antibody levels include the following :
- History of measles infection
- History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
- History of measles exposure
Predictor of inadequate measles antibody levels include the following :
- Born outside Thailand
- History of staying outside Thailand for long time in childhood
- Living in the rural area for a long period in childhood
- Fail to participate school system on time
- Conditions
- Measles
- Keywords
- measles, antibody, prevalence, predictors, Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old, Measles antibody levels, Predictors of adequate measles antibody levels and inadequate measles antibody levels
- Medical subject headings
- Measles
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adequate antimeales antibody levels | ELISA test OD > 0.1 | |
| Inadequate measles antibody levels | ELISA test OD < 0.1 |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2012 (estimated)
- Study startJul 2012
- Primary completionJan 2013 (estimated)
- Study completionMar 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MeaslesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 550 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen Saovabha Memorial Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jaruboot Angsanakul, Queen Saovabha Memorial Institute
- Investigators
- Jaruboot Angsanakul, M.D., Principal investigator, Queen Saovabha Memorial Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01602094
- Sponsor's protocol ID
- TAI5501
- Status last verified
- May 2012
- First submitted
- 16 May 2012
- Last updated
- 18 May 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
- ClinicalTrials.gov ID
- NCT01602094
- Acronym / sponsor ID
- TAI5501
- Conditions
- Measles
- Keywords
- measles, antibody, prevalence, predictors, Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old, Measles antibody levels, Predictors of adequate measles antibody levels and inadequate measles antibody levels
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 550 participants (estimated)
- Lead sponsor
- Queen Saovabha Memorial InstituteUniversity, hospital or other
- Study start
- Jul 2012
- Primary completion
- Jan 2013 (estimated)
- Study completion
- Mar 2013 (estimated)
- First posted
- 18 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prevalence of participants who have protective immunity to measles virus is less than ninety percent.
Predictor of adequate measles antibody levels include the following :
- History of measles infection
- History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
- History of measles exposure
Predictor of inadequate measles antibody levels include the following :
- Born outside Thailand
- History of staying outside Thailand for long time in childhood
- Living in the rural area for a long period in childhood
- Fail to participate school system on time
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Adequate antimeales antibody levels | – | –ELISA test OD > 0.1 |
| Inadequate measles antibody levels | – | –ELISA test OD < 0.1 |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Health Thai participant age 18-30 years old.
Key inclusion criteria (1 listed)
- Age 18-30 years old
Key exclusion criteria (4 listed)
- Last measles vaccination less than 10 years of age
- Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
- Receiving blood or blood product within 3 months
- Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2012.
- Contact informationLink provided by the sponsor.
Related trials for Measles
Recruiting
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Iron Deficiencies
RecruitingPhase 4
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
Heart Transplant Infection Prevention
Active, not recruitingPhase 1/2
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Not yet recruitingPhase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
Measles, Mumps
RecruitingPhase 1
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jaruboot Angsanakul, M.D. principal investigator
Queen Saovabha Memorial Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Measles, run by Queen Saovabha Memorial Institute at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 May 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jaruboot Angsanakul, M.D. (662-252-0161-4 ext. 132, jaruboot@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2012.